Omeros Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
39,796.00
73,673.00
75,096.00
66,745.00
53,481.00
126,757
Depreciation, Depletion & Amortization
302.00
326.00
209.00
300.00
551.00
962
Other Funds
-
-
10,000.00
4,844.00
-
30,695
Funds from Operations
32,699.00
62,837.00
62,946.00
45,291.00
36,055.00
108,029
Changes in Working Capital
3,004.00
4,793.00
2,263.00
6,213.00
172.00
4,292
Net Operating Cash Flow
29,695.00
58,044.00
65,209.00
51,504.00
36,227.00
103,737
Capital Expenditures
204.00
28.00
240.00
126.00
350.00
Purchase/Sale of Investments
8,113.00
6,185.00
20,366.00
16,209.00
37,248.00
Net Investing Cash Flow
7,909.00
6,157.00
20,606.00
16,335.00
37,598.00
Issuance/Reduction of Debt, Net
-
11,235.00
14,891.00
22,662.00
431.00
Net Financing Cash Flow
21,650.00
50,857.00
86,826.00
68,698.00
74,995.00
Net Change in Cash
136.00
1,030.00
1,011.00
859.00
1,170.00
Free Cash Flow
29,899.00
58,072.00
65,449.00
51,630.00
36,577.00
Change in Capital Stock
21,650.00
39,622.00
81,935.00
41,192.00
75,426.00

About Omeros

View Profile
Address
The Omeros Building
Seattle Washington 98119
United States
Employees -
Website http://www.omeros.com
Updated 07/08/2019
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.